Form 4: Hologic CEO Stephen MacMillan Acquires Shares Through Performance Stock Units

Hologic's CEO, Stephen MacMillan, reports acquiring 118,560 shares of common stock through performance stock units, increasing his direct and indirect holdings.

Summary

• Stephen MacMillan, the Chairman, President, and CEO of Hologic Inc., reported a transaction on November 5, 2024.
• He acquired 118,560 shares of Hologic common stock through performance stock units.
• These performance stock units had their performance criteria satisfied but remain subject to service-based vesting requirements.
• The performance stock units are settled in shares of common stock on a one-for-one basis.
• Following the transaction, MacMillan directly owns 1,276,122 shares of common stock.
• He also indirectly owns 1,146,829 shares through the MacMillan Family Trust.
• Included in his direct holdings are 1,079,673 restricted stock units/performance stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing insider transactions. The CEO acquiring shares is generally a positive sign, but it's not a major event.

Positives

• The acquisition of shares by the CEO could be interpreted positively, signaling confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the CEO's increased stake could imply a positive outlook.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates